Disc Medicine's (IRON) Outperform Rating Reiterated at Raymond James

Raymond James reissued their outperform rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a report issued on Monday morning, Marketbeat reports. The brokerage currently has a $40.00 target price on the stock, down from their prior target price of $75.00. A number of other research firms have also recently commented on IRON. […]

Related Keywords

United States ,America ,Kevin Bitterman ,Raymond James ,Steward Partners Investment Advisory ,Cantor Fitzgerald ,Morgan Stanley ,Nasdaq ,Securities Exchange Commission ,Disc Medicine Inc ,Venture Fund Xlp Atlas ,America Corp ,Ameritas Investment Partners Inc ,Disc Medicine ,Free Report ,Moderate Buy ,Get Free Report ,Venture Fund ,Exchange Commission ,Director Kevin Bitterman ,Investment Partners ,Partners Investment Advisory ,Disc Medicine Daily ,Nasdaq Iron ,Iron ,Medical ,Reiterated Rating ,